Acrobiosystems Co

Acrobiosystems Co EBITDA Margin

The EBITDA Margin of Acrobiosystems Co (301080.SZ) as of Oct 16, 2026 is 23.50 %. In the previous year, EBITDA Margin was 23.28 % — a change of 0.94% (higher).

EBITDA Margin

23.50 %

YoY

0.94%

Last updated:

EBITDA Margin of Acrobiosystems Co is 2025 23.50 % . EBITDA Margin of Acrobiosystems Co was 2024 23.28 % . It decreases by 0.94% higher compared to the previous year.

The Acrobiosystems Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
18.13 CNY
Jan 1, 2019
17.86 CNY
Jan 1, 2020
58.34 CNY
Jan 1, 2021
53.50 CNY
Jan 1, 2022
40.00 CNY
Jan 1, 2023
29.77 CNY
Jan 1, 2024
23.28 CNY
Jan 1, 2025
23.50 CNY
The Acrobiosystems Co EBITDA Margin history
YEAREBITDA MarginYoY
23.50 %+0.94%
23.28 %-21.80%
29.77 %-25.57%
40.00 %-25.23%
53.50 %-8.30%
58.34 %+226.59%
17.86 %-1.44%
18.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd is a biotechnology company based in Beijing, China, operating within the Health Care sector. The company specializes in the development of biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, and related products such as kits, antibodies, fillers, and culture media. With 597 full-time employees, Acrobiosystems provides services and products primarily for research and development (R&D) and production processes in the pharmaceutical and biotechnology industries. Its offerings support early drug discovery, verification, drug screening, optimization, diagnostic reagent development, and preclinical and clinical trials for various diseases, including tumors, autoimmune disorders, cardiovascular conditions, and infectious diseases. The company completed its initial public offering (IPO) on October 18, 2021, and is listed under the ticker symbol 301080.SZ with ISIN CNE100004S13. Acrobiosystems operates from its headquarters in Beijing, leveraging its technological expertise to contribute to advancements in drug development and diagnostic solutions. The company's website is https://www.acrobiosystems.cn/. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

EBITDA Margin of Acrobiosystems Co is 23.50 % in 2025.

EBITDA Margin of Acrobiosystems Co changed from 23.28 % to 23.50 %, representing a 0.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co